Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO

Imbria Pharmaceuticals, Inc., a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases with high unmet need, today announced the successful closing of a $57.5 million Series B financing with a top-tier syndicate of life science investors led by new investor, Deep Track Capital. Additional new investors participating in the financing include AN Ventures, Catalio Capital Management and Cytokinetics, Inc. Existing investors RA Capital Management and SV Health Investors also contributed to the financing.

Proceeds to support advancement of ninerafaxstat for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM), with initiation of Phase 2b clinical trial planned in Q2 2025. Current Executive Chair, Alvin Shih, MD appointed as CEO; Rebecca Luse, Managing Director at Deep Track Capital, appointed to Board of Directors.

For the full announcement, please see Imbria’s press release here.

 
About AN Venture Partners

ANV is a Tokyo and San Francisco-based biotech venture capital firm. ANV is dedicated to building high impact global biotech companies and specializes in sourcing scientific opportunities from Japan.

Media Contacts
Email: info@an.vc